Please login to the form below

Not currently logged in
Email:
Password:

FDA must come to decision on Omnitrope, says judge

Sandoz confident that generic version of biotech drug will gain regulatory approval

The US Food and Drug Administration (FDA) must decide whether to approve or reject an application by Novartis' generics unit, Sandoz, to market a drug to treat growth disorders, a federal judge has ruled.

In September 2005, Sandoz filed a suit against the FDA alleging that it violated federal law by failing to come to a decision on its marketing application for Omnitrope, a version of human growth hormone.

The issue reflects the current grey area surrounding approvals of generic versions of biotechnology drugs. With patents on the oldest biotech drugs beginning to expire, the generics industry is exerting pressure on the US government to formulate clear legislation on the approval process for generic versions.

While the FDA said it did not identify any deficiencies in the Omnitrope application, it said it had not been able to come to a final decision due to uncertainty regarding scientific and legal issues.

Ricardo Urbina, a judge in the US District Court for the District of Columbia said in an opinion that the FDA is required to meet a statutory deadline in its decisions on whether to approve drugs. He wrote that the agency had ìidentified no compelling reason for its court to excuse its delayî.

Sandoz could have the option of a hearing before the Secretary of Health and Human Services.

In a statement, Sandoz said it ìlooks forward to FDA's decision and expects a positive outcomeî.

Sandoz is currently waiting for the European Commission to grant final marketing authorisation before Omnitrope can be sold in Europe.

30th September 2008

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics